Ascendis Pharma AS (STU:A71) EPS (Basic) : €-6.57 (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Ascendis Pharma AS EPS (Basic)?

Ascendis Pharma AS's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was €-0.64. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €-6.57.

Ascendis Pharma AS's EPS (Diluted) for the three months ended in Dec. 2024 was €-0.64. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-6.57.

Ascendis Pharma AS's EPS without NRI for the three months ended in Dec. 2024 was €-0.64. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -6.57.

During the past 3 years, the average EPS without NRI Growth Rate was 10.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -4.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -23.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Ascendis Pharma AS's highest 3-Year average EPS without NRI Growth Rate was 10.70% per year. The lowest was -68.10% per year. And the median was -28.30% per year.

Ascendis Pharma AS EPS (Basic) Historical Data

The historical data trend for Ascendis Pharma AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS EPS (Basic) Chart

Ascendis Pharma AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-8.28

-7.00

-10.40

-8.55

-6.53

Ascendis Pharma AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-1.54	-2.30	-1.91	-1.72	-0.64

Ascendis Pharma AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ascendis Pharma AS's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-378.084	-	0)	/	57.892
	=	-6.53

Ascendis Pharma AS's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-38.469	-	0)	/	59.799
	=	-0.64

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.57

Ascendis Pharma AS (STU:A71) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ascendis Pharma AS EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (STU:A71) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

ASND:USA ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

https://www.ascendispharma.com

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Ascendis Pharma AS Headlines

No Headlines